Okinawa Prefecture is an endemic area of Strongyloides stercoralis infection. Since treat ment of this infection remains unsatisfactory, we evaluated the efficacy of ivermectin. Twenty three patients were treated with a single oral dose of ivermectin (mean ± SD, 105.5 ± 20.8 meg/ kg of body weight), followed by a second dose two weeks later. The rate of cure was 85.7% at 2 weeks after the first treatment, and 90.5% at 2 weeks after the second treatment. Side effects occurred in 2 patients (8.7%), but they were mild and transient. The results indicate that ivermectin might be useful and relatively safe for the therapy of Strongyloides stercoralis infection as an alternative to thiabendazole or mebendazole. (Internal Medicine 31: 310-312, 1992) 
Introduction
Although the incidence of Strongyloides stercoralis (S. stercoralis) infection in Okinawa Prefecture was found to be less than 2% of the population when determined by traditional methods, it was proven to be 6.2% by a new technique, the agar plate method (1) (2) (3) . Thiabendazole is strongly active in eradicating the organism, but it is well known that the rate of severe side effects is extremely high (4) (5) (6) . Mebendazole is also active against S. ster coralis (7, 8) , but a high incidence of liver disfunction was shown in our previous studies (9, 10) . Ivermectin (IVM) has recently been found to be safe and effective for treatment of human onchocerciasis (ll-14) and lymphatic filariasis (15), but there are only two published reports concerning the efficacy of IVM against S. ster coralis in humans (16, 17). We therefore attempted to evaluate the efficacy of IVM against S. stercoralis infection. Materials and Methods
Study Subjects
Twenty-three patients, 16 males and 7 females, with a positive 5. stercoralis stool culture were included in this study. They ranged in age from 47 to 77 years with a mean age of 62 years.
Treatment Protocol IVM (Merck Sharp & Dohme Research Laboratories, New Jersey, USA) was given in a signle dose of 6mg one hour before breakfast and this treatment was repeated 2 weeks later. The dosages of IVM ranged from 68.4 to 160.0 mcg/kg of body weight. Parasitological Examination Fresh fecal samples, obtained before treatment, 2 weeks after the first treatment and 2 weeks after the second treatment, were examined using the agar plate method. Clinical Examination Clinical examination was done before treatment, 2 weeks after the initial treatment and 2 weeks after the second treatment. The examinations included a clinical history, a complete blood count, serum-chemistry studies, serological studies and urinalysis.
Results

Pretreatment Evaluation
Of the 23 patients, 9 patients (39.1%) had no com plaints before the treatment. Fourteen patients com plained of some symptoms, including abdominal pain Efficacy of IVM against S. stercoralis (n = 2), and constipation (n = 2). There were no abnormal laboratory data except eosinophilia and elevation of IgE. The former occurred in 34.8% of the patients, and the latter was detected in 39.1% of the patients.
Antiparasitic Effect
The parasitological eradication rate at 2 weeks after the initial treatment was 85.7% (18 of 21 patients) and 2 weeks after the second course was 90.5% (19 of 21 patients). Three patients were uncured, their dosages of IVM were 133.3, 78.9 and 113.2mcg/kg of body wt. Parasitological diagnosis is sometimes difficult because S. stercoralis larvae in the stool may be very few and inconsistently present. However, the new method, the agar plate method, is more efficient than the traditional methods (direct stool smear method, filter paper culture method and formalin-ether concentration method) (1 -3). S. stercoralis infection is usually asymptomatic and limited to the intestine. However, severe systemic disease due to S. stercoralis may develop in patients suffering from wasting diseases or malnutrition, or who are receiv ing immunosuppressive therapy or corticosteroids. Therefore, S. stercoralis infection should be treated with an effective and active drug. Although thiabendazole is effective against S. stercoralis, severe side effects occur (4-6). We recently treated 24 patients with 100 mg of meben dazole twice a day for 28 days in accordance with the reports of successful treatment of S. stercoralis, those reports also indicated only mild and infrequent side effects of the drug (7, 8) . Although the eradication rate for our patients was 83.3%, the incidence of liver dis function was 71.4% of the patients (9). We then treated 47 patients for 5 day periods, repeating the treatment at 1, 3 and 4 weeks following the initial 5 day treatment. The eradication rate was 100% , but liver disfunction still occurred in 48.9% of the patients (10) . IVM is a semisynthetic macrocyclic lactone (a fer mentation product of an actinomycete, Streptomyces avermitilis). Although it has been found to be micro filaricidal in clinical trials in humans, its precise action mechanism is unknown (18, 19). A series of clinical trials of IVM showed that a dose of 150mcg/kg was safe and effective for onchocerciasis therapy (20). There are only two reports concerning the efficacy of IVM against S. stercoralis in humans. Freedman and his colleagues (16) reported that IVM was 100% effective against strongyloidiasis (3 patients, with dosages of IVM ranging from 140 to 200 mcg/kg). Naquira and colleagues (17) described results in which the cure rate at 30 days after treatment averaged 88% (101 patients, dosages of IVM were 50, 100, 150, 200, 100x2, 200x2mcg/kg). Although the cure rates were significantly higher in recipients of doses >150 mcg/kg, there was no significant varience above that dose. In this study all patients were given 6mg of IVM and the dosage of uncured patients was <150 mcg/kg. Therefore, it would have been possible to eradicate the infection if those patients had received a higher dose of the drug. We conclude that IVM is an effective drug for the treatment of S. stercoralis and that it also causes minimal side effects. 
Side Effects
